**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 54868

**Manuscript type:** Minireviews

**Treatment of gastrointestinal bleeding in left ventricular assist devices: a comprehensive review**

Vedachalam S *et al*. Treatment of LVAD-related gastrointestinal bleeding

Srikanth Vedachalam, Gokulakrishnan Balasubramanian, Garrie J Haas, Somashekar G Krishna

**Srikanth Vedachalam,** Department of Internal Medicine,The Ohio State University Wexner Medical Center; Columbus, OH 43210, United States

## Gokulakrishnan Balasubramanian, Somashekar G Krishna, Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center; Columbus, OH 43210, United States

**Garrie J Haas,** Division of Cardiovascular Medicine,The Ohio State University Wexner Medical Center; Columbus, OH 43210, United States

**Author contributions:** Vedachalam S and Krishna SG designed the structure of this manuscript; Vedachalam S, Krishna SG, and Balasubramanian G drafted the manuscript and contributed critical revisions to this manuscript; Haas GJ contributed critical revisions to this manuscript.

**Corresponding author: Somashekar G Krishna, MD, Associate Professor, Director of Clinical Research,** Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, 395 W. 12th Avenue, Suite 262, Columbus, OH 43210, United States. somashekar.krishna@osumc.edu

**Received:** February 25, 2020

**Revised:** May 2, 2020

**Accepted:** May 14, 2020

**Published online:** May 28, 2020

**Abstract**

Left ventricular assist devices (LVAD) are increasingly become common as life prolonging therapy in patients with advanced heart failure. Current devices are now used as definitive treatment in some patients given the improved durability of continuous flow pumps. Unfortunately, continuous flow LVADs are fraught with complications such as gastrointestinal (GI) bleeding that are primarily attributed to the formation of arteriovenous malformations. With frequent GI bleeding, antiplatelet and anticoagulation therapies are usually discontinued increasing the risk of life-threatening events. Small bowel bleeds account for 15% as the source and patients often undergo multiple endoscopy procedures. Treatment strategy includes resuscitation measures and endoscopic therapies. Medical treatment is with octreotide. Novel treatment options include thalidomide, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers, estrogen-based hormonal therapies, doxycycline, desmopressin and bevacizumab. Current research has explored the mechanism of frequent GI bleeds in this population, including destruction of von Willebrand factor, upregulation of tissue factor, vascular endothelial growth factor, tumor necrosis factor-α, tumor growth factor-β, and angiopoetin-2, and downregulation of angiopoetin-1. In addition, healthcare resource utilization is only increasing in this patient population with higher admissions, readmissions, blood product utilization, and endoscopy. While some of the novel endoscopic and medical therapies for LVAD bleeds are still in their development stages, these tools will yet be crucial as the number of LVAD placements will likely only increase in the coming years.

**Key words:** Left ventricular assist device; push enteroscopy; double balloon enteroscopy; video capsule endoscopy; octreotide; bevacizumab; gastrointestinal bleeding

Vedachalam S, Balasubramanian G, Haas GJ, Krishna SG. Treatment of gastrointestinal bleeding in left ventricular assist devices: A comprehensive review. *World J Gastroenterol* 2020; 26(20): 2550-2558

URL: https://www.wjgnet.com/1007-9327/full/v26/i20/2550.htm

DOI: https://dx.doi.org/10.3748/wjg.v26.i20.2550

**Core tip:** Left ventricular assist devices are becoming increasingly common as life-prolonging therapy in advanced heart failure. However, left ventricular assist devices have shown high rates of gastrointestinal bleeding with 18%-40% of patients having episodes of bleed. Arteriovenous malformations are primarily responsible, which can be both challenging to control and cause many patients to discontinue essential anti-platelet and anti-coagulation therapies. Small bowel lesions are common in this population, frequently requiring small bowel endoscopic evaluation. For refractory cases, medical management is required including octreotide, thalidomide, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers, estrogen-based therapies, desmopressin, doxycycline or bevacizumab to prevent further gastrointestinal bleeding.

**Introduction**

Left Ventricular Assist Devices (LVAD) are becoming increasingly common for end-stage heart failure with 20000+ devices placed a year in over 180 hospitals around the United States and growing[1]. These devices are used either as a bridge to heart transplantation or as definitive, destination therapy, which owe their success in part to continuous flow technology which improves pump durability. Unfortunately, current devices appear to increase the incidence of gastrointestinal (GI) bleeding, which is seen in 18-40% of patients that have received an LVAD[2-7]. This is a major contributor to increased morbidity and mortality, where there is a 5-fold increased risk for readmission due to GI bleeding[8]. These episodes lead to recurrent hospitalizations, increased lengths of stay, costs, blood transfusions, and time off anticoagulation and antiplatelet therapy, which significantly increases the risk of pump thrombosis and stroke[8]. Furthermore, as many of these patients are being bridged to transplant, the increased number of blood transfusions may lead to higher antibody production (allosensitization), thus limiting the donor pool and prolonging the time to transplant. In this review we aim to summarize current literature addressing the management of GI bleeding in patients with LVADs.

**Etiology and Pathophysiology**

Among all GI bleeding in patients with LVADs, 47% of the episodes originated from the upper GI tract, 22% are from the lower GI tract, 15% are from the midgut (ligament of Treitz to the ileocecal valve), and nearly 19% remain unknown[5]. Arteriovenous malformations (AVM) account for 29%-44% of GI bleeding in this population, and many are found in the midgut[5,9]. These lesions can be notoriously hard to treat, as they are frequently multiple lesions throughout the GI tract and bleed intermittently leading to unremarkable endoscopic evaluations[5]. Other common lesions include gastritis (22%), peptic ulcer disease (13%), diverticular hemorrhage (6%), colonic polyps (5%), and colitis (4%), with the remaining causes unknown[10].

Both *in vitro* and *in vivo* studies have investigated the etiology of increased AVMs in LVAD patients, which has lead to the development of current therapeutics. Biomarkers studied include von Willebrand factor (vWF), tumor growth factor-β (TGF-β)**,** tissue factor (TF), vascular endothelial growth factor (VEGF), tumor necrosis factor-α (TNF-α), and angiopoietin 1 and 2. Von Willebrand factor (vWF) is significantly broken down in LVAD patients. According to Bartoli et al, there is a “2-hit hypothesis”. The first hit includes the degradation of vWF causing acquired vWF deficiency (due to sheer stress creating protein unraveling, making vWF susceptible to ADAMSTS-13 breakdown), contributing to reduced interaction of vWF-platelet and vWF-collagen. The second hit involves these smaller vWF causing upregulation of angiogenesis and AVM formation in LVAD patients[11]. TNF-α has been reported to induce pericyte apoptosis, TF and angiopoietin-2 expression, and vascular instability leading to increased risk of AVM-related bleeds[12]. Likewise VEGF and TGF-β have been similarly upregulated in LVAD patients and implicated in these bleeds[3,5,12,13]. Angiopoietin-1, which normally is associated with vascular stability, is downregulated in patients with LVAD[3]. These factors affecting AVM formation and stability lead to an increased risk of GI bleeding and dictate many medical therapies that will be discussed in this review (Figure 1).

***Acute GI bleeding management***

**Medical management:** Gastrointestinal bleeding is a significant issue in LVAD patients leading to the discontinuation of antiplatelet and anticoagulation therapy. Initial management for acute GI bleeding include IV fluid resuscitation, electrolyte replacement, packed red blood cell transfusion to hemoglobin goals of 7-9 g/dl, and discontinuation of antiplatelet (acetylsalicylic acid (ASA) and P2Y12 inhibitors) and anticoagulation (Coumadin) medications[14-16]. After an acute episode, antiplatelet drugs may be restarted and anticoagulation may be rechallenged with either the same International Normalized Ratio (INR) goal (typically 1.5-3.5) or at a reduced goal[17,18]. Those patients with a high frequency of GI bleeding may have both antiplatelet and anticoagulation medications discontinued for an extended period of time, thus imparting significant risk for LVAD thrombosis.

While present day continuous flow devices have several advantages over the older pulsatile pumps, they have been implicated in the higher risk for the formation of AVMs and increased GI bleeding. It is thought that continuous flow LVADs lead to intestinal hypoperfusion, local hypoxia, vascular dilation, and AVM formation[19]. One technique that can be instituted to reduce GI bleeding is reducing the pump speed under ECHO guidance to increase pulsating flow while ensuring adequate LV off-loading[5]. One study looking at the factors of GI bleeds in LVAD patients found decreases in GI bleeding rates with only small decreases in pump speed (HeartMate II 9560 rpm vs 9490 rpm, P < 0.001; HeartWare 2949 rpm *vs* 2710 rpm, P < 0.001)[20].

Other conservative management strategies for active GI bleeding and prevention of future episodes include prophylactic proton pump inhibitor (PPI) use and reversal of anticoagulation. PPIs are often prescribed to LVAD patients, especially when they have had prior episodes of GI bleeding. However, the risk reduction of further GI bleeding is marginal as the majority of bleeding are from AVMs. PPI use was similar between those that did have GI bleeding versus those that did not in a study observing 101 LVAD patients (*p* = 0.47)[18].

Reversal of anticoagulation is typically done with a combination of vitamin K (oral or IV), fresh frozen plasma (FFP) and/or prothrombin complex concentrate (PCC). There is currently a lack of high-quality, prospective large-scale studies providing recommendations on specific regimens and dosings. However, one review article on anticoagulation reversal has suggested using IV vitamin K and PCC in hemodynamically significant bleeding[21]. Since FFPs require crossmatching, time for thawing, increased volume per unit administered in a fluid sensitive population, and have a higher risk of transfusion-related reactions, PCC is preferred for reversal of anticoagulation[21]. Ultimately, there remains high variability of dosages used throughout the literature, and differing indications for reversal of anticoagulation which often remains largely at the discretion of the treating provider. Following the reversal of anticoagulation, varying rates of thromboembolic events have been reported. While older studies utilizing recombinant activated factor VII at “high-doses” (30-70 µg/kg) revealed thromboembolic event rate of 36.7%[22], more recent literature quote rates of 2.9% (1 of 38) and suggest that larger doses of reversal agents can still have low rates of thromboembolism[4].

**Endoscopic therapy:** A treatment algorithm is shown in Figure 2. Endoscopic evaluation and treatment is frequently performed in LVAD patients given their high rates of GI bleeding. Most patients will receive an esophagogastroduodenoscopy (EGD) and/or colonoscopy on the initial presentation with concerns for GI bleeding. If these evaluations are unremarkable, the next step would be to consider a repeat EGD, given the high rates of upper GI bleeds, with possible push enteroscopy to explore small bowel sources, and repeat a colonoscopy if the initial colonoscopy prep was suboptimal[7,16].

Push enteroscopy allows for evaluation of the small bowel and most commonly to the proximal jejunum. Marsano et al found that EGD had high rates of detection (45%), however many required repeat endoscopy at a rate of 1.8 endoscopes per patient in their study. On repeat endoscopy the majority underwent push enteroscopy with a high small bowel detection rate of 80% in repeat bleeding episodes with 25% of their patients having jejunal lesions[23].

A significant portion of LVAD-related GI bleeding come from the midgut/unknown origins, which makes evaluation of the small bowel important in this population. While there may be some conflicting data that balloon (single or double) enteroscopy is superior, however, according to the American Society of Gastrointestinal Endoscopy (ASGE) guidelines, it is still recommended to proceed with video capsule endoscopy (VCE) as first line evaluation of the small bowel[15]. This is safe technique with no electromagnetic interference to LVADs or implantable cardioverter-defibrillators (ICD) devices[24]. One study showed initial VCE had a diagnostic yield of 58.5% versus proceeding with double balloon enteroscopy first that had a yield of 41.5%[25]. Not only does VCE have a greater diagnostic yield, but also is helpful in deciding the subsequent endoscopic approach based on the presumed location of the bleed. Further, there is an increased overall yield of 7% with double balloon enteroscopy if done after VCE[25].

Double balloon enteroscopy (DBE) allows clinicians to use a “push-and-pull” technique to visualize the small bowel. In the realm of obscure GI bleeding, the diagnostic yield of this technique was found to be 56 % (95%CI: 48.9%-62.1%) in one large meta-analysis[26]. Specifically in LVAD patients with GI bleeding, the diagnostic yield with DBE was 69%[27]. In this study, 10 patients underwent 13 DBEs for 11 episodes of melena and 2 episodes of hematochezia. Mid-bowel lesions were found 56% of the times, while 33% of lesions were in the proximal bowel, and 11% were in both proximal and mid bowel. The most common lesions identified were AVMs, consisting of 44% of the discovered lesions.

AVMs are often found in LVAD patients and are commonly treated with contact or non-contact thermal therapy [argon plasma coagulation (APC)] given the large, diffuse nature of these lesions[16]. One study showed that APC treatment of colonic AVMs could significantly decrease blood transfusions and increase overall hemoglobin in a 16-mo follow-up[28]. However, the upper/midgut predominance of AVMs in LVAD patients versus the classic right colonic location of AVMs in non-LVAD patient may change the nature of these AVMs. In addition, the tendency of increased anticoagulation in LVAD patients may cause APC to be less effective in LVAD patients, and may even provoke future bleeding episodes as APC can cause ulceration[29]. Clinicians should carefully consider the use of APC in LVAD patients, and may benefit from alternative methods to control bleed endoscopically or with the medical therapies discussed below. According to the European Society of Gastroenterology (ESGE), there is not enough evidence to prescribe treatment recommendations for AVM lesions at this time[14].

Apart from thermal therapy, other endoscopic treatment options for AVMs and other sources of GI bleeding found in LVAD patients include epinephrine injection, electrocautery, endoclips, band ligation, acrylic glue and hemostatic spray/powder[15,16,30,31]. With large bleeding ulcers, it is recommended to approach these lesions with “dual therapy”, typically with epinephrine and another modality[14]. Hemostatic spray is currently not seen as “conventional” therapy and used in setting of “salvage” therapy[24,30]. One study looking at TC-325, hemostatic powder, showed a 90.7% primary hemostasis rate with a rebleeding rate of 26.1%. It was, however, found to be less effective in patients on anticoagulation, like LVAD patients, with a hemostasis rate of 63%[30].

***Prophylactic medications: arteriovenous malformation targeted medical therapy***

The diffuse nature AVM are responsible for many cases of bleeding/rebleeding in LVAD patients; up to 29%-44%. Endoscopy may be able to identify an acutely bleeding lesion, but one bleeding AVM lesion usually portends others along the GI tract that may bleed in the future, as well as the formation of new AVMs. Therefore, medical therapy targeted at the driving factors of these lesions have been used to reduce the episodes of rebleeding and ultimately decrease the number of hospitalizations, endoscopic procedures and blood transfusions.

**Octreotide:** After conservative medical therapy is tried and failed, a common first agent that is used to reduce recurrent GI bleeding in LVAD patients is octreotide, a somatostatin analogue. It is believed that octreotide reduces bleeding rates by decreasing portal venous pressures due to splenic vasodilation, enhancing platelet aggregation, and inhibiting of angiogenesis in the GI tract through downregulation of VEGF and suppression of digestive enzymes[5,32]. Octreotide is currently dosed 50 to 100 μg subcutaneous (SQ) twice daily (BID) or octreotide long-acting release (LAR) 20 to 30 mg intramuscularly (IM) monthly. A study observing the effects of octreotide LAR 20 mg IM monthly in LVAD patients showed a significant reduction of bleeding events in their 26 patient cohort (20 Heartmate II, 5 HVAD, and 1 HeartAssist). The average number of bleeding episodes pre-treatment was 3 ± 2.4 per year in this group with improvement to 0.7 ± 1.3 per year after initiation of monthly octreotide. 43% of the cohort was free of further bleeding episodes in follow-up[13]. Furthermore, AVM lesions were found 44% of the times on endoscopy prior to octreotide therapy, but only 28% of the times afterwards.[13] Long acting 20 mg depot octreotide has also been studied in a prophylactic setting started within 1 mo of LVAD implant in a phase I trial of 10 patients that prevented any GI bleeding episodes within the first four months when otherwise typical rates are 39% within the first 2 mo after implantation[32,33].

Octreotide is seen currently as the first line agent, but does have some potential side effects that need to be discussed with patients. These side effects include diarrhea, abdominal pain, nausea, vomiting, gallstone formation, glucose abnormalities, pruritis, hypothyroidism, headaches and dizziness[34].

**Thalidomide:** Thalidomide has been used for several indications over the years since it was initially synthesized in the 1950s, including for morning sickness, sedation, and Kaposi sarcoma treatment. LVAD patients have benefited from thalidomide for its anti-angiogenesis effect through its ability to downregulate VEGF and basic fibroblastic growth factor (bFGF)[35]. This has been shown to reduce the rate of recurrent AVM-related bleeds. In a study that tested thalidomide 100 mg daily versus iron supplementation daily (control) in non-LVAD patient for four months showed a 50% or greater reduction in the rate of GI bleeding in 71.4% of patients on thalidomide versus only 3.7% in the control group over a one year follow-up. 46.4% of patients in thalidomide arm had complete cessation of further bleeds versus 0% in the control arm[35]. Recently, a 2019 study of 17 LVAD patients receiving thalidomide showed favorable results with a reduction of GI bleeding from an average 4.6 episodes per year to 0.4 episodes per year. Additionally, blood transfusions reduced from 36.1 to 0.9 units of transfusions per year. In this study 50 mg of thalidomide was used daily or twice daily with uptitration to 100 mg twice daily with bleeding episodes[6].

However, there are some notable shortcomings with thalidomide. Thalidomide has been shown to have a relatively high adverse effect rate; ranging from 58-71%[6,36]. The more common adverse events encountered were dizziness, neuropathy, fatigue, constipation, transaminitis, and somnolence. There does seem to be dose-dependent response in adverse effects with 87.5% of patients improving with lower doses of thalidomide. Additionally, access and cost are both seemingly issues. Thalidomide is generally cost-prohibitive if not covered by insurance, and prior authorization is typically needed; delaying drug initiation. In Namdaran et al, bridging with octreotide was used on average for 11 d while approval was received and could be used as a workaround[6]. Finally, both prescriber and pharmacist need to be approved by the THALOMID Risk Evaluation and Mitigation Strategy program to prescribe the thalidomide, which limit the number of providers that can offer this therapy.

**angiotensin converting enzyme inhibitors/angiotensin II receptor blockers:** Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) are common cardiac medications that appear to have a benefit in preventing recurrent GI bleeding in LVAD patients. Houston et al looked at 131 LVAD patients and recorded whether or not they were on an ACEi or ARB for at least 30 days with LVAD support.[3] This study found that of the 31 patients that did not receive an ACEi or an ARB, 48% had a GI bleeding episode with 29% of those being related to AVMs; while only 24% of those that received an ACEi or ARB had GI bleeding and only 9% were related to AVMs. Ultimately, an OR 0.29 for all causes of GI bleed, along with an OR 0.23 for AVM bleeds were found. It is thought the mechanism mainly centers around the downregulation of TGF-β, which normally upregulates VEGF. In addition, these agents create a blockade of angiotensin-II from acting upon angiotensin I receptors, causing a downregulation of the angiogenesis.

Their study also looked at dosing of these medications and failed to show a dose-dependence on its ability to reduce AVM-related bleeds[3].The effect of ACEi/ARB on AVM lesions seem to be separate to its blood pressure effect as beta-blockers and calcium channel blockers independently tested in LVAD patients did not produce the same results in decreasing the number of GI bleeds that ACEi/ARBs were able to. Additional studies are needed to validate the effect of ACEi/ARBs in this population.

**Estrogen-based hormone therapy:** Hormone therapies, either estrogen-only or estrogen in combination with progesterone, have been studied in the prevention of AVM bleeds with conflicting results. One multicentered, randomized, controlled trial studied 72 non-LVAD patients that used ethinylestradiol 0.01 mg daily and norethisterone 2 mg daily versus placebo for at least a year. This trial did not show a significant difference between the two arms. Treatment failure rate was 39% vs 46% between hormone therapy and control, respectively. Likewise, the number of bleeding episodes, transfusion requirements, severe adverse events and mortality did not differ significantly between groups[37].Contrarily, isolated case reports have evaluated individual LVAD patients with remarkable results reducing frequent GI bleeds through the use of estrogen-based therapies[35,38]. Overall, the benefits of hormone therapy are theorized to be caused by improved vascular endothelium integrity and reduced bleeding times[5].The literature available for hormone therapy in LVAD patients is very sparse. Furthermore, the concerns for thromboembolism with estrogen-based therapies will likely give pause to many practitioners in this already pro-thrombotic population without further large-scaled studies.

**Doxycycline:** Doxycycline is a relatively inexpensive medication that is widely used in both the short-term setting to treat pneumonia to chronic management in inflammatory acne. Bartoli et al conducted an in vitro study looking at the prospect of using doxycycline to reduce LVAD bleeds by stabilizing ADAMTS-13[11]. High shear stress was added to human plasma samples with high doses of doxycycline (0.6 to 20 mg/dl). vWF degradation was greatly diminished with 10 out of the 11 degradation fragments reduced from baseline by 12% ± 2% when doxycycline was added. It was found that doxycycline reduced the plasma and recombinant forms of ADAMTS-13 activity in these suprashear stress environments. Additionally, vWF: collagen binding was increased with doxycycline and resulted in overall improved platelet aggregation without hyperactivating platelets to increase thrombosis formation. This showed promising in vitro results, but dosages of doxycycline that were effective ranged from 5-20 mg/dl, which far exceeds the 0.3 to 0.5 mg/dl most patients receive today. While this is below toxic limits of 2000 mg/kg in rat models, further testing will surely need to occur before this therapy becomes mainstream. To date, there is sparse other data on doxycycline use in LVAD patients.

**Desmopressin:** Desmopressin is a vasopressin analog that is currently approved for use in patients with either hemophilia A or mild-to-moderate von Willebrand disease (type I), and may also have its use in LVAD patients to reduce GI bleeding[39]. There are isolated case reports of achieving control of GI bleeding secondary to LVAD[2]. vWF multimers are in gross deficit in LVAD patients, as noted in this review. Desmopressin has the ability to increase the amount of vWF by 150%-200% at the 150 mcg dose[2]. Although there are potential adverse effects of hyponatremia and fluid retention with desmopressin, which can be detrimental to patients with poor right-sided cardiac function and may require intensified oral diuretic regimens[2]. Overall, this medication still shows promise. Again the literature is sparse and larger studies are needed.

**Bevacizumab:** Preliminary results from a single institutional study show remarkable results from bevacizumab, a humanized monoclonal antibody against VEGF, in lowering the rate of GI bleeding in refractory cases[40]. This study evaluated 5 patients with LVAD and showed annual decreases in blood product usage from 45.8 to 6.0 units, reduced hospitalizations per year from 5.6 to 1.7 and an annual reduction in endoscopy from 10.6 to 2.3 procedures. Bevacizumab was well tolerated without side effects in the study participants. As with other novel agents, further studies are necessary.

**Conclusion**

GI bleeding is a frequent complication of LVAD placement due to the continuous flow LVAD devices causing dysregulation of angiogenesis-related biomarkers and sheer stress. Conservative methods such as reducing anticoagulation doses and discontinuing antiplatelet and anticoagulation therapies are unsafe and not successful in most instances. The AVMs are frequently located in the midgut and pose challenges with routine endoscopy. Video capsule endoscopy has a high diagnostic yield and should be performed after unremarkable EGD and colonoscopy in most cases. Afterward, prompt push enteroscopy, or DBE is recommended to treat lesions before they stop bleeding, as well as to reduce the number of blood products transfused in LVAD patients. Octreotide is a commonly used medication in GI bleeding and is the first line agent for those with refractory bleeding. ACEi/ARB may have secondary benefits in reducing AVM-related bleeding. Some case studies indicate the role of estrogen-based hormone therapies, doxycycline, and desmopressin. Other medications with significant side effects need to be evaluated in larger studies, including thalidomide and bevacizumab. With the increase of durable LVAD placements each year, we will manage more frequent instances of GI bleeding, and it will be important to continue to refine diagnostic and therapeutic methods to treat and prevent these episodes.

**References**

1 **Kirklin JK**, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB, Naftel DC. Eighth annual INTERMACS report: Special focus on framing the impact of adverse events. *J Heart Lung Transplant* 2017; **36**: 1080-1086 [PMID: 28942782 DOI: 10.1016/j.healun.2017.07.005]

2 **Hollis IB**, Chen SL, Chang PP, Katz JN. Inhaled Desmopressin for Refractory Gastrointestinal Bleeding in a Patient With a HeartMate II Left Ventricular Assist Device. *ASAIO J* 2017; **63**: e47-e49 [PMID: 27556142 DOI: 10.1097/MAT.0000000000000433]

3 **Houston BA**, Schneider AL, Vaishnav J, Cromwell DM, Miller PE, Faridi KF, Shah A, Sciortino C, Whitman G, Tedford RJ, Stevens GR, Judge DP, Russell SD, Rouf R. Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. *J Heart Lung Transplant* 2017; **36**: 380-385 [PMID: 28169115 DOI: 10.1016/j.healun.2016.12.016]

4 **Jennings DL**, Rimsans J, Connors JM. Prothrombin Complex Concentrate for Warfarin Reversal in Patients with Continuous-Flow Left Ventricular Assist Devices: A Narrative Review. *ASAIO J* 2020; **66**: 482-488 [PMID: 31192853 DOI: 10.1097/MAT.0000000000001021]

5 **Molina TL**, Krisl JC, Donahue KR, Varnado S. Gastrointestinal Bleeding in Left Ventricular Assist Device: Octreotide and Other Treatment Modalities. *ASAIO J* 2018; **64**: 433-439 [PMID: 29406356 DOI: 10.1097/MAT.0000000000000758]

6 **Namdaran P**, Zikos TA, Pan JY, Banerjee D. Thalidomide Use Reduces Risk of Refractory Gastrointestinal Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices. *ASAIO J* 2019; Online ahead of print [PMID: 31425265 DOI: 10.1097/MAT.0000000000001054]

7 **Zikos TA**, Pan J, Limketkai B, Banerjee D, Fernandez-Becker N. Efficacy of Video Capsule Endoscopy in the Management of Suspected Small Bowel Bleeding in Patients With Continuous Flow Left Ventricular Assist Devices. *Gastroenterology Res* 2017; **10**: 280-287 [PMID: 29118868 DOI: 10.14740/gr908w]

8 **Shah R**, Qayed E. Outcomes and Predictors of Readmissions with GI Bleeding in Patients with Left Ventricular Assist Devices. *South Med J* 2018; **111**: 666-673 [PMID: 30392001 DOI: 10.14423/SMJ.0000000000000883]

9 **Malik S**, Malik SA, Ulmer LL, Jha LK, Strupp MS, Raichlin E, Lyden ER, Hewlett AT. Gastrointestinal Bleeding With Left Ventricular Assist Devices (LVAD): Locating the Leak and Identifying Outcomes. *J Clin Gastroenterol* 2019; **53**: e202-e207 [PMID: 29688916 DOI: 10.1097/MCG.0000000000001041]

10 **Draper KV**, Huang RJ, Gerson LB. GI bleeding in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis. *Gastrointest Endosc* 2014; **80**: 435-446.e1 [PMID: 24975405 DOI: 10.1016/j.gie.2014.03.040]

11 **Bartoli CR**, Zhang DM, Hennessy-Strahs S, Kang J, Restle DJ, Bermudez C, Atluri P, Acker MA. Clinical and In Vitro Evidence That Left Ventricular Assist Device-Induced von Willebrand Factor Degradation Alters Angiogenesis. *Circ Heart Fail* 2018; **11**: e004638 [PMID: 30354363 DOI: 10.1161/CIRCHEARTFAILURE.117.004638]

12 **Tabit CE**, Coplan MJ, Chen P, Jeevanandam V, Uriel N, Liao JK. Tumor necrosis factor-α levels and non-surgical bleeding in continuous-flow left ventricular assist devices. *J Heart Lung Transplant* 2018; **37**: 107-115 [PMID: 28651907 DOI: 10.1016/j.healun.2017.06.001]

13 **Juricek C**, Imamura T, Nguyen A, Chung B, Rodgers D, Sarswat N, Kim G, Raikhelkar J, Ota T, Song T, Burkhoff D, Sayer G, Jeevanandam V, Uriel N. Long-Acting Octreotide Reduces the Recurrence of Gastrointestinal Bleeding in Patients With a Continuous-Flow Left Ventricular Assist Device. *J Card Fail* 2018; **24**: 249-254 [PMID: 29427603 DOI: 10.1016/j.cardfail.2018.01.011]

14 **Karstensen JG**, Ebigbo A, Aabakken L, Dinis-Ribeiro M, Gralnek I, Le Moine O, Vilmann P, Ijoma U, Anigbo G, Afihene M, Duduyemi B, Ponchon T, Hassan C. Nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Cascade Guideline. *Endosc Int Open* 2018; **6**: E1256-E1263 [PMID: 30302383 DOI: 10.1055/a-0677-2084]

15 **ASGE Standards of Practice Committee**, Gurudu SR, Bruining DH, Acosta RD, Eloubeidi MA, Faulx AL, Khashab MA, Kothari S, Lightdale JR, Muthusamy VR, Yang J, DeWitt JM. The role of endoscopy in the management of suspected small-bowel bleeding. *Gastrointest Endosc* 2017; **85**: 22-31 [PMID: 27374798 DOI: 10.1016/j.gie.2016.06.013]

16 **ASGE Standards of Practice Committee**, Pasha SF, Shergill A, Acosta RD, Chandrasekhara V, Chathadi KV, Early D, Evans JA, Fisher D, Fonkalsrud L, Hwang JH, Khashab MA, Lightdale JR, Muthusamy VR, Saltzman JR, Cash BD. The role of endoscopy in the patient with lower GI bleeding. *Gastrointest Endosc* 2014; **79**: 875-885 [PMID: 24703084 DOI: 10.1016/j.gie.2013.10.039]

17 **Baumann Kreuziger L**, Karkouti K, Tweddell J, Massicotte MP. Antithrombotic therapy management of adult and pediatric cardiac surgery patients. *J Thromb Haemost* 2018; **16**: 2133-2146 [PMID: 30153372 DOI: 10.1111/jth.14276]

18 **Aggarwal A**, Pant R, Kumar S, Sharma P, Gallagher C, Tatooles AJ, Pappas PS, Bhat G. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. *Ann Thorac Surg* 2012; **93**: 1534-1540 [PMID: 22541185 DOI: 10.1016/j.athoracsur.2012.02.035]

19 **Nascimbene A**, Neelamegham S, Frazier OH, Moake JL, Dong JF. Acquired von Willebrand syndrome associated with left ventricular assist device. *Blood* 2016; **127**: 3133-3141 [PMID: 27143258 DOI: 10.1182/blood-2015-10-636480]

20 **Lopilato AC**, Doligalski CT, Caldeira C. Incidence and Risk Factor Analysis for Gastrointestinal Bleeding and Pump Thrombosis in Left Ventricular Assist Device Recipients. *Artif Organs* 2015; **39**: 939-944 [PMID: 25912789 DOI: 10.1111/aor.12471]

21 **Holbrook A**, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; **141**: e152S-e184S [PMID: 22315259 DOI: 10.1378/chest.11-2295]

22 **Bruckner BA**, DiBardino DJ, Ning Q, Adeboygeun A, Mahmoud K, Valdes J, Eze J, Allison PM, Cooley DA, Gregoric ID, Frazier OH. High incidence of thromboembolic events in left ventricular assist device patients treated with recombinant activated factor VII. *J Heart Lung Transplant* 2009; **28**: 785-790 [PMID: 19632574 DOI: 10.1016/j.healun.2009.04.028]

23 **Marsano J**, Desai J, Chang S, Chau M, Pochapin M, Gurvits GE. Characteristics of gastrointestinal bleeding after placement of continuous-flow left ventricular assist device: a case series. *Dig Dis Sci* 2015; **60**: 1859-1867 [PMID: 25616611 DOI: 10.1007/s10620-015-3538-7]

24 **Rondonotti E**, Spada C, Adler S, May A, Despott EJ, Koulaouzidis A, Panter S, Domagk D, Fernandez-Urien I, Rahmi G, Riccioni ME, van Hooft JE, Hassan C, Pennazio M. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Technical Review. *Endoscopy* 2018; **50**: 423-446 [PMID: 29539652 DOI: 10.1055/a-0576-0566]

25 **Brito HP**, Ribeiro IB, de Moura DTH, Bernardo WM, Chaves DM, Kuga R, Maahs ED, Ishida RK, de Moura ETH, de Moura EGH. Video capsule endoscopy *vs* double-balloon enteroscopy in the diagnosis of small bowel bleeding: A systematic review and meta-analysis. *World J Gastrointest Endosc* 2018; **10**: 400-421 [PMID: 30631404 DOI: 10.4253/wjge.v10.i12.400]

26 **Teshima CW**, Kuipers EJ, van Zanten SV, Mensink PB. Double balloon enteroscopy and capsule endoscopy for obscure gastrointestinal bleeding: an updated meta-analysis. *J Gastroenterol Hepatol* 2011; **26**: 796-801 [PMID: 21155884 DOI: 10.1111/j.1440-1746.2010.06530.x]

27 **Edwards AL**, Mönkemüller K, Pamboukian SV, George JF, Wilcox CM, Peter S. Utility of double-balloon enteroscopy in patients with left ventricular assist devices and obscure overt gastrointestinal bleeding. *Endoscopy* 2014; **46**: 986-991 [PMID: 25290096 DOI: 10.1055/s-0034-1377512]

28 **Kwan V**, Bourke MJ, Williams SJ, Gillespie PE, Murray MA, Kaffes AJ, Henriquez MS, Chan RO. Argon plasma coagulation in the management of symptomatic gastrointestinal vascular lesions: experience in 100 consecutive patients with long-term follow-up. *Am J Gastroenterol* 2006; **101**: 58-63 [PMID: 16405534 DOI: 10.1111/j.1572-0241.2006.00370.x]

29 **Zikos TA**, Namdaran P, Banerjee D, Friedland S, Pan JY. Arteriovenous malformations respond poorly to argon plasma coagulation in patients with continuous flow left ventricular assist devices. *Eur J Gastroenterol Hepatol* 2019; **31**: 792-798 [PMID: 31150365 DOI: 10.1097/MEG.0000000000001427]

30 **de Rezende DT**, Brunaldi VO, Bernardo WM, Ribeiro IB, Mota RCL, Baracat FI, de Moura DTH, Baracat R, Matuguma SE, de Moura EGH. Use of hemostatic powder in treatment of upper gastrointestinal bleeding: a systematic review and meta-analysis. *Endosc Int Open* 2019; **7**: E1704-E1713 [PMID: 31803822 DOI: 10.1055/a-0977-2897]

31 **Ribeiro IB**, Rezende DT, Madruga Neto AC, Ide E, Furuya CK, De Moura DTH, De Moura EGH. Endoscopic dual therapy for giant peptic ulcer hemorrhage. *Endoscopy* 2018; **50**: E316-E317 [PMID: 30107634 DOI: 10.1055/a-0665-4142]

32 **Malhotra R**, Shah KB, Chawla R, Pedram S, Smallfield MC, Priday AG, DeWilde CT, Brophy DF. Tolerability and Biological Effects of Long-Acting Octreotide in Patients With Continuous Flow Left Ventricular Assist Devices. *ASAIO J* 2017; **63**: 367-370 [PMID: 27922890 DOI: 10.1097/MAT.0000000000000491]

33 **Jabbar HR**, Abbas A, Ahmed M, Klodell CT Jr, Chang M, Dai Y, Draganov PV. The Incidence, Predictors and Outcomes of Gastrointestinal Bleeding in Patients with Left Ventricular Assist Device (LVAD). *Dig Dis Sci* 2015; **60**: 3697-3706 [PMID: 26072320 DOI: 10.1007/s10620-015-3743-4]

34 **Borna RM**, Jahr JS, Kmiecik S, Mancuso KF, Kaye AD. Pharmacology of Octreotide: Clinical Implications for Anesthesiologists and Associated Risks. *Anesthesiol Clin* 2017; **35**: 327-339 [PMID: 28526153 DOI: 10.1016/j.anclin.2017.01.021]

35 **D'Amato RJ**, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. *Proc Natl Acad Sci USA* 1994; **91**: 4082-4085 [PMID: 7513432 DOI: 10.1073/pnas.91.9.4082]

36 **Ge ZZ**, Chen HM, Gao YJ, Liu WZ, Xu CH, Tan HH, Chen HY, Wei W, Fang JY, Xiao SD. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. *Gastroenterology* 2011; **141**: 1629-37.e1-4 [PMID: 21784047 DOI: 10.1053/j.gastro.2011.07.018]

37 **Junquera F**, Feu F, Papo M, Videla S, Armengol JR, Bordas JM, Saperas E, Piqué JM, Malagelada JR. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. *Gastroenterology* 2001; **121**: 1073-1079 [PMID: 11677198 DOI: 10.1053/gast.2001.28650]

38 **Gutsche JT**, Atluri P, Augoustides JG. Treatment of ventricular assist-device-associated gastrointestinal bleeding with hormonal therapy. *J Cardiothorac Vasc Anesth* 2013; **27**: 939-943 [PMID: 24054188 DOI: 10.1053/j.jvca.2013.05.019]

39 **Cushing M**, Kawaguchi K, Friedman KD, Mark T. Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease. *Transfusion* 2012; **52**: 1535-1541 [PMID: 22229973 DOI: 10.1111/j.1537-2995.2011.03500.x]

40 **Asleh R**, Schettle SD, Maltais S, Daly RC, Iyer V, Stulak JM, Rodeheffer R. Promising Novel Treatment with Intravenous Bevacizumab for Refractory Gastrointestinal Bleeding from Angiodysplastic Lesions in Patients Supported with a Continuous-Flow Left Ventricular Assist Device: A Pilot Study. *J Heart Lung Transplant* 2019; **38**: S135 [DOI: 10.1016/j.healun.2019.01.320]

**Footnotes**

**Conflict-of-interest statement:** None of the authors have any conflicts of interest or financial ties to disclose related to the current study.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 25, 2020

**First decision:** April 22, 2020

**Article in press:** May 14, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0


Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Ribeiro IB **S-Editor:** Gong ZM **L-Editor:** A **E-Editor:** Zhang YL

**Figure Legends**

**Figure 1 Pathophysiology of gastrointestinal bleeding in left ventricular assist device patients.** LVAD: left ventricular assist device; vWF: von Willebrand factor.

****

**Figure 2 Treatment algorithm for left ventricular assist device-related gastrointestinal bleeding.** Angiogram and tagged RBC scan are two common imaging modality to elucidate locations of bleed for further intervention.Iron deficiency is a common with chronic hemolysis in left ventricular assist device patients. Iron replacement can be initiated after checking iron studies. LVAD: left ventricular assist device; GI: gastrointestinal.